Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

21 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
A randomized, double-blind, multicenter, parallel group study to compare relative efficacies of the topical gels 3% erythromycin/5% benzoyl peroxide and 0.025% tretinoin/erythromycin 4% in the treatment of moderate acne vulgaris of the face.
Gupta AK, Lynde CW, Kunynetz RA, Amin S, Choi K, Goldstein E. Gupta AK, et al. J Cutan Med Surg. 2003 Jan-Feb;7(1):31-7. doi: 10.1007/s10227-002-2101-2. Epub 2002 Oct 9. J Cutan Med Surg. 2003. PMID: 12362264 Clinical Trial.
Acitretin Use in Dermatology.
Guenther LC, Kunynetz R, Lynde CW, Sibbald RG, Toole J, Vender R, Zip C. Guenther LC, et al. Among authors: kunynetz r. J Cutan Med Surg. 2017 Nov/Dec;21(3_suppl):2S-12S. doi: 10.1177/1203475417733414. Epub 2017 Sep 27. J Cutan Med Surg. 2017. PMID: 28952335 Review.
Canadian consensus on skin barrier repair therapy in atopic dermatitis.
Thomas R, Landells I, Lynde C, Withers M, Weinstein M, Kunynetz R, Haber R, Balbul A, Dion PL. Thomas R, et al. Among authors: kunynetz r. J Cutan Med Surg. 2012 Mar-Apr;16 Suppl 1:S1-15. doi: 10.2310/7750.2012.S1PEDIA. J Cutan Med Surg. 2012. PMID: 23577504 No abstract available.
Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials.
Papp KA, Menter MA, Abe M, Elewski B, Feldman SR, Gottlieb AB, Langley R, Luger T, Thaci D, Buonanno M, Gupta P, Proulx J, Lan S, Wolk R; OPT Pivotal 1 and OPT Pivotal 2 investigators. Papp KA, et al. Br J Dermatol. 2015 Oct;173(4):949-61. doi: 10.1111/bjd.14018. Br J Dermatol. 2015. PMID: 26149717 Clinical Trial.
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.
Griffiths CE, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, Cameron GS, Erickson J, Zhang L, Secrest RJ, Ball S, Braun DK, Osuntokun OO, Heffernan MP, Nickoloff BJ, Papp K; UNCOVER-2 and UNCOVER-3 investigators. Griffiths CE, et al. Lancet. 2015 Aug 8;386(9993):541-51. doi: 10.1016/S0140-6736(15)60125-8. Epub 2015 Jun 10. Lancet. 2015. PMID: 26072109 Clinical Trial.
Evidence that a neutrophil-keratinocyte crosstalk is an early target of IL-17A inhibition in psoriasis.
Reich K, Papp KA, Matheson RT, Tu JH, Bissonnette R, Bourcier M, Gratton D, Kunynetz RA, Poulin Y, Rosoph LA, Stingl G, Bauer WM, Salter JM, Falk TM, Blödorn-Schlicht NA, Hueber W, Sommer U, Schumacher MM, Peters T, Kriehuber E, Lee DM, Wieczorek GA, Kolbinger F, Bleul CC. Reich K, et al. Among authors: kunynetz ra. Exp Dermatol. 2015 Jul;24(7):529-35. doi: 10.1111/exd.12710. Epub 2015 May 8. Exp Dermatol. 2015. PMID: 25828362 Free PMC article. Clinical Trial.
Long-term safety of ivermectin 1% cream vs azelaic acid 15% gel in treating inflammatory lesions of rosacea: results of two 40-week controlled, investigator-blinded trials.
Stein Gold L, Kircik L, Fowler J, Jackson JM, Tan J, Draelos Z, Fleischer A, Appell M, Steinhoff M, Lynde C, Sugarman J, Liu H, Jacovella J; Ivermectin Phase 3 Study Group. Stein Gold L, et al. J Drugs Dermatol. 2014 Nov;13(11):1380-6. J Drugs Dermatol. 2014. PMID: 25607706 Clinical Trial.
21 results